Novo Nordisk presents Phase 3 REIMAGINE trial results for CagriSema in type 2 diabetes at ADA 2026

  • Novo Nordisk flagged new clinical data across its cardiometabolic pipeline for presentation at the ADA Scientific Sessions in New Orleans on June 5-8, 2026.
  • Phase 3 REIMAGINE 1-3 results are set to give a clearer read on CagriSema’s ability to improve blood sugar control and support weight loss in type 2 diabetes.
  • Mid-stage trial findings for once-weekly injectable zenagamtide are due to outline its safety profile and early efficacy in type 2 diabetes.
  • Additional Ozempic and Wegovy analyses will be presented, reinforcing semaglutide’s broader cardiometabolic positioning across multiple conditions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief on May 27, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.